These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23675504)

  • 1. Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.
    Røe K; Bratland Å; Vlatkovic L; Ragnum HB; Saelen MG; Olsen DR; Marignol L; Ree AH
    PLoS One; 2013; 8(5):e63723. PubMed ID: 23675504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
    Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
    Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.
    Dagvadorj A; Kirken RA; Leiby B; Karras J; Nevalainen MT
    Clin Cancer Res; 2008 Mar; 14(5):1317-24. PubMed ID: 18316550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
    Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
    Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.
    Røe K; Mikalsen LT; van der Kogel AJ; Bussink J; Lyng H; Ree AH; Marignol L; Olsen DR
    Radiat Oncol; 2012 May; 7():75. PubMed ID: 22621752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
    Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
    Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
    Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
    Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
    Tan SH; Nevalainen MT
    Endocr Relat Cancer; 2008 Jun; 15(2):367-90. PubMed ID: 18508994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.
    Koptyra M; Gupta S; Talati P; Nevalainen MT
    Int J Biochem Cell Biol; 2011 Oct; 43(10):1417-21. PubMed ID: 21704724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
    Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
    Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
    Seedhouse SJ; Affronti HC; Karasik E; Gillard BM; Azabdaftari G; Smiraglia DJ; Foster BA
    Prostate; 2016 Mar; 76(4):359-68. PubMed ID: 26642837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.
    Tan SH; Dagvadorj A; Shen F; Gu L; Liao Z; Abdulghani J; Zhang Y; Gelmann EP; Zellweger T; Culig Z; Visakorpi T; Bubendorf L; Kirken RA; Karras J; Nevalainen MT
    Cancer Res; 2008 Jan; 68(1):236-48. PubMed ID: 18172316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
    Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.
    Dagvadorj A; Tan SH; Liao Z; Xie J; Nurmi M; Alanen K; Rui H; Mirtti T; Nevalainen MT
    Int J Biochem Cell Biol; 2010 Dec; 42(12):2037-46. PubMed ID: 20854925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT5A/B gene locus undergoes amplification during human prostate cancer progression.
    Haddad BR; Gu L; Mirtti T; Dagvadorj A; Vogiatzi P; Hoang DT; Bajaj R; Leiby B; Ellsworth E; Blackmon S; Ruiz C; Curtis M; Fortina P; Ertel A; Liu C; Rui H; Visakorpi T; Bubendorf L; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Nevalainen MT
    Am J Pathol; 2013 Jun; 182(6):2264-75. PubMed ID: 23660011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.
    Liao Z; Lutz J; Nevalainen MT
    Int J Biochem Cell Biol; 2010 Feb; 42(2):186-92. PubMed ID: 19914392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.
    Mirtti T; Leiby BE; Abdulghani J; Aaltonen E; Pavela M; Mamtani A; Alanen K; Egevad L; Granfors T; Josefsson A; Stattin P; Bergh A; Nevalainen MT
    Hum Pathol; 2013 Mar; 44(3):310-9. PubMed ID: 23026195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.
    Gu L; Dagvadorj A; Lutz J; Leiby B; Bonuccelli G; Lisanti MP; Addya S; Fortina P; Dasgupta A; Hyslop T; Bubendorf L; Nevalainen MT
    Am J Pathol; 2010 Apr; 176(4):1959-72. PubMed ID: 20167868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.